Quemliclustat for Healthy Subjects

This trial tests how the body processes quemliclustat, a new drug, in healthy adult males. Researchers aim to understand how the drug leaves the body by measuring its presence in blood, urine, and feces after a single dose. Participants should be healthy non-smokers with a Body Mass Index (BMI) between 18 and 32, and no recent history of drug or alcohol abuse. As a Phase 1 trial, participants will be among the first to help researchers understand how this new treatment works in people.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

Research has shown that quemliclustat was tested for safety in earlier studies. The data indicates that when combined with other treatments, quemliclustat was generally safe and tolerable. It did not significantly increase harmful effects when added to standard therapies. However, some serious side effects were reported, such as a drop in certain white blood cells (neutropenia) and low red blood cell levels (anemia), occurring in a significant number of patients and presenting more severely.

Quemliclustat is unique because it involves a new approach to treatment by using a radiolabeled compound, [14C]-quemliclustat, delivered through an IV infusion. Unlike traditional treatments that may require multiple doses or oral administration, this single-dose infusion could offer insights into the drug's absorption and distribution in the body. Researchers are excited about this method because it allows them to closely track how quemliclustat moves and acts within the body, potentially leading to more precise and effective treatments in the future.

Research has shown promising results for quemliclustat in earlier studies. In one study, patients who received treatments including quemliclustat lived an average of 15.7 months, longer than usual for some types of cancer. Another study found that quemliclustat reduced the risk of death by 37% and extended survival by nearly 6 months compared to other treatments. Early data also indicate that quemliclustat is generally safe and well-tolerated when administered through an IV. These findings suggest that quemliclustat could be effective for certain conditions, but more research is needed.¹²³⁶⁷